|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MEIS1 |
Gene summary for MEIS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MEIS1 | Gene ID | 4211 |
| Gene name | Meis homeobox 1 | |
| Gene Alias | MEIS1 | |
| Cytomap | 2p14 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | O00470 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4211 | MEIS1 | CA_HPV_1 | Human | Cervix | CC | 3.99e-08 | -2.84e-01 | 0.0264 |
| 4211 | MEIS1 | N_HPV_1 | Human | Cervix | N_HPV | 1.72e-03 | -2.53e-01 | 0.0079 |
| 4211 | MEIS1 | CCI_1 | Human | Cervix | CC | 5.81e-05 | 9.57e-01 | 0.528 |
| 4211 | MEIS1 | CCI_2 | Human | Cervix | CC | 1.19e-07 | 1.22e+00 | 0.5249 |
| 4211 | MEIS1 | CCI_3 | Human | Cervix | CC | 1.85e-09 | 8.81e-01 | 0.516 |
| 4211 | MEIS1 | sample3 | Human | Cervix | CC | 8.71e-03 | -2.26e-01 | 0.1387 |
| 4211 | MEIS1 | AEH-subject1 | Human | Endometrium | AEH | 6.66e-12 | 4.88e-01 | -0.3059 |
| 4211 | MEIS1 | AEH-subject2 | Human | Endometrium | AEH | 2.28e-21 | 4.89e-01 | -0.2525 |
| 4211 | MEIS1 | AEH-subject3 | Human | Endometrium | AEH | 3.24e-06 | 1.28e-01 | -0.2576 |
| 4211 | MEIS1 | AEH-subject4 | Human | Endometrium | AEH | 2.12e-09 | 2.59e-01 | -0.2657 |
| 4211 | MEIS1 | AEH-subject5 | Human | Endometrium | AEH | 2.89e-07 | 2.25e-01 | -0.2953 |
| 4211 | MEIS1 | EEC-subject1 | Human | Endometrium | EEC | 1.00e-06 | 3.00e-01 | -0.2682 |
| 4211 | MEIS1 | EEC-subject2 | Human | Endometrium | EEC | 5.89e-33 | 7.70e-01 | -0.2607 |
| 4211 | MEIS1 | EEC-subject3 | Human | Endometrium | EEC | 1.12e-19 | -3.71e-01 | -0.2525 |
| 4211 | MEIS1 | EEC-subject4 | Human | Endometrium | EEC | 1.17e-05 | 1.33e-01 | -0.2571 |
| 4211 | MEIS1 | EEC-subject5 | Human | Endometrium | EEC | 7.33e-09 | 3.60e-01 | -0.249 |
| 4211 | MEIS1 | GSM5276934 | Human | Endometrium | EEC | 7.91e-19 | -3.73e-01 | -0.0913 |
| 4211 | MEIS1 | GSM5276935 | Human | Endometrium | EEC | 1.21e-15 | -3.56e-01 | -0.123 |
| 4211 | MEIS1 | GSM5276937 | Human | Endometrium | EEC | 4.67e-14 | -3.86e-01 | -0.0897 |
| 4211 | MEIS1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.38e-21 | -1.41e-02 | -0.1869 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
| GO:004563710 | Cervix | CC | regulation of myeloid cell differentiation | 48/2311 | 210/18723 | 1.49e-05 | 2.93e-04 | 48 |
| GO:00605375 | Cervix | CC | muscle tissue development | 76/2311 | 403/18723 | 9.76e-05 | 1.27e-03 | 76 |
| GO:00147064 | Cervix | CC | striated muscle tissue development | 72/2311 | 384/18723 | 1.76e-04 | 2.07e-03 | 72 |
| GO:0033002 | Cervix | CC | muscle cell proliferation | 49/2311 | 248/18723 | 5.43e-04 | 5.24e-03 | 49 |
| GO:00486386 | Cervix | CC | regulation of developmental growth | 61/2311 | 330/18723 | 7.69e-04 | 6.85e-03 | 61 |
| GO:0014855 | Cervix | CC | striated muscle cell proliferation | 18/2311 | 76/18723 | 4.45e-03 | 2.71e-02 | 18 |
| GO:0150063 | Cervix | CC | visual system development | 63/2311 | 375/18723 | 6.58e-03 | 3.65e-02 | 63 |
| GO:0001654 | Cervix | CC | eye development | 62/2311 | 371/18723 | 7.83e-03 | 4.13e-02 | 62 |
| GO:0045665 | Cervix | CC | negative regulation of neuron differentiation | 16/2311 | 69/18723 | 8.75e-03 | 4.48e-02 | 16 |
| GO:0048880 | Cervix | CC | sensory system development | 63/2311 | 381/18723 | 9.29e-03 | 4.66e-02 | 63 |
| GO:003009925 | Cervix | N_HPV | myeloid cell differentiation | 33/534 | 381/18723 | 1.61e-08 | 2.52e-06 | 33 |
| GO:004563723 | Cervix | N_HPV | regulation of myeloid cell differentiation | 21/534 | 210/18723 | 6.68e-07 | 4.00e-05 | 21 |
| GO:190370623 | Cervix | N_HPV | regulation of hemopoiesis | 29/534 | 367/18723 | 8.22e-07 | 4.74e-05 | 29 |
| GO:00615151 | Cervix | N_HPV | myeloid cell development | 10/534 | 71/18723 | 3.17e-05 | 8.16e-04 | 10 |
| GO:00987511 | Cervix | N_HPV | bone cell development | 7/534 | 34/18723 | 4.07e-05 | 9.70e-04 | 7 |
| GO:00603482 | Cervix | N_HPV | bone development | 15/534 | 205/18723 | 8.27e-04 | 1.02e-02 | 15 |
| GO:0030219 | Cervix | N_HPV | megakaryocyte differentiation | 6/534 | 57/18723 | 5.54e-03 | 3.94e-02 | 6 |
| GO:006053722 | Cervix | N_HPV | muscle tissue development | 21/534 | 403/18723 | 6.10e-03 | 4.21e-02 | 21 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| MEIS1 | BAS | Cervix | CC | MEIS1-AS2,LINC01798,PECAM1, etc. | 8.26e-04 |  |
| MEIS1 | COL | Cervix | CC | MEIS1-AS2,LINC01798,PECAM1, etc. | 5.12e-03 | |
| MEIS1 | MES | Cervix | N_HPV | MEIS1-AS2,LINC01798,PECAM1, etc. | 4.56e-02 |  |
| MEIS1 | CT | Colorectum | SER | SPIB,ADCY5,NBPF19, etc. | 6.67e-02 |  |
| MEIS1 | PERI | Lung | IAC | NCALD,SETBP1,PRICKLE2, etc. | 4.60e-01 |  |
| MEIS1 | STM | Pancreas | Healthy | AC091607.2,NLK,TDRD3, etc. | 5.19e-02 |  |
| MEIS1 | EE | Stomach | CAG | MEIS2,GAST,ERO1B, etc. | 1.67e-01 |  |
| MEIS1 | EE | Stomach | CSG | MEIS2,GAST,ERO1B, etc. | 2.47e-01 |  |
| MEIS1 | A.X | Stomach | GC | MEIS2,GAST,ERO1B, etc. | 7.35e-02 |  |
| MEIS1 | EE | Stomach | SIM | MEIS2,GAST,ERO1B, etc. | 1.13e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MEIS1 | SNV | Missense_Mutation | novel | c.1051N>A | p.Asp351Asn | p.D351N | O00470 | protein_coding | deleterious(0) | benign(0.057) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| MEIS1 | SNV | Missense_Mutation | c.826N>T | p.Arg276Cys | p.R276C | O00470 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| MEIS1 | SNV | Missense_Mutation | novel | c.220N>T | p.Asp74Tyr | p.D74Y | O00470 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MEIS1 | SNV | Missense_Mutation | novel | c.883N>G | p.Leu295Val | p.L295V | O00470 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
| MEIS1 | deletion | Frame_Shift_Del | c.921_927delGTTGGCA | p.Gln307HisfsTer11 | p.Q307Hfs*11 | O00470 | protein_coding | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| MEIS1 | insertion | Frame_Shift_Ins | novel | c.522_523insTGTATCTTTGC | p.Ser175CysfsTer7 | p.S175Cfs*7 | O00470 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MEIS1 | insertion | Nonsense_Mutation | novel | c.524_525insATGATTCAAGCCATACAAGTATTAAGGTTTCAT | p.Ser175delinsArgTerPheLysProTyrLysTyrTerGlyPheIle | p.S175delinsR*FKPYKY*GFI | O00470 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MEIS1 | SNV | Missense_Mutation | c.140N>G | p.Ser47Trp | p.S47W | O00470 | protein_coding | tolerated(0.12) | possibly_damaging(0.708) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MEIS1 | SNV | Missense_Mutation | rs780370917 | c.178N>A | p.Ala60Thr | p.A60T | O00470 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MEIS1 | SNV | Missense_Mutation | c.65C>T | p.Thr22Met | p.T22M | O00470 | protein_coding | deleterious(0.02) | possibly_damaging(0.508) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |